文献速递临床生化临床免疫

成纤维细胞生长因子23:将分析改进转化为慢性肾脏病三级预防的临床有效性

Fibroblast growth factor 23: translating analytical improvement into clinical effectiveness for tertiary prevention in chronic kidney disease.
PubMed 文献 · Clin Chem Lab Med · 2022-08-26

本文综述了FGF23在慢性肾脏病(CKD)及其相关心血管疾病中的病理生理作用,重点评估ELISA法检测FGF23的分析性能问题(稳定性差、分析性能欠佳)导致误导性结果,而近期获批的化学发光法完整iFGF23检测经严格分析验证后,已能初步评估心血管和肾脏事件的风险阈值,并有望捕捉治疗调节引起的iFGF23临床相关变化。

要点

  • ELISA法检测FGF23因稳定性和分析性能问题,目前无法确立其在CKD中的临床有效性。
  • 化学发光法完整iFGF23检测经严格分析验证后,可初步评估心血管和肾脏事件的风险阈值。
  • FGF23的分析优化有望将生理学与流行病学结合,并推动向临床结局的转化。

核心结论

  • FGF23的临床有效性取决于检测方法的全面分析验证。
  • ELISA法检测FGF23因稳定性问题及分析性能欠佳,目前无法在CKD中确立临床有效性。
  • 近期获批的化学发光法完整iFGF23检测经严格分析验证后,已能初步评估心血管和肾脏事件的风险阈值,并有望捕捉治疗调节引起的iFGF23临床相关变化。

研究设计与样本

  • 本文为综述,对文献进行了全面的批判性评价,聚焦于FGF23检测方法的分析性能及其在CKD中的临床有效性。

主要发现

  • ELISA法检测FGF23的稳定性问题及分析性能欠佳是释放误导性结果的主要原因。
  • Meta分析方法在单研究结果高度异质性的情况下未能报告明确证据。
  • 化学发光法完整iFGF23检测经严格分析验证后,已能初步评估心血管和肾脏事件的风险阈值。

临床怎么用

  • 在临床引入FGF23检测前,应确保检测方法经过全面分析验证。
  • 化学发光法完整iFGF23检测可用于初步评估心血管和肾脏事件的风险阈值。

局限性

  • 目前无法确立ELISA法检测FGF23在CKD中的临床有效性。
  • Meta分析方法在单研究结果高度异质性下未能提供明确证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Fibroblast growth factor 23 (FGF23) plays a key role in the pathophysiology of chronic kidney disease (CKD) and of the associated cardiovascular diseases, ranking on the crossroads of several evolving areas with a relevant impact on the health-care system (ageing, treatment of CKD and prevention from cardiovascular and renal events). In this review, we will critically appraise the overall issues concerning the clinical usefulness of FGF23 determination in CKD, focusing on the analytical performances of the methods, aiming to assess whether and how the clinical introduction of FGF23 may promote cost-effective health care policies in these patients. CONTENT: Our comprehensive critical appraisal of the literature revealed that we are currently unable to establish the clinical usefulness of FGF23 measured by ELISA in CKD, as stability issues and suboptimal analytical performances are the major responsible for the release of misleading results. The meta-analytical approach has failed to report unambiguous evidence in face of the wide heterogeneity of the results from single studies. SUMMARY AND OUTLOOK: Our review has largely demonstrated that the clinical usefulness depends on a thorough analytical validation of the assay. The recent introduction of chemiluminescent intact-FGF23 (iFGF23) assays licensed for clinical use, after passing a robust analytical validation, has allowed the actual assessment of preliminary risk thresholds for cardiovascular and renal events and is promising to capture the iFGF23 clinically relevant changes as a result of a therapeutic modulation. In this perspective, the analytical optimization of FGF23 determination may allow a marriage between physiology and epidemiology and a merging towards clinical outcomes.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Ferraro S, Biganzoli G, Calcaterra V, et al. Fibroblast growth factor 23: translating analytical improvement into clinical effectiveness for tertiary prevention in chronic kidney disease. Clin Chem Lab Med. 2022. PMID: 36008874. doi:10.1515/cclm-2022-0635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。